Related Experiment Videos
Transforming growth factor-beta and megakaryocytes in the pathogenesis of idiopathic myelofibrosis
M C Martyré1, N Romquin, M C Le Bousse-Kerdiles
1Unité 365 INSERM, Institut Curie, Section de Biologie, Paris, France.
Abstract:
Although the disease is well described, the pathogenesis of bone marrow fibrosis in idiopathic myelofibrosis still remains unclear. We previously reported elevated intraplatelet transforming growth factor-beta (TGF-beta) levels in patients with this myeloproliferative disorder, compared with healthy subjects. Here, in a series of 16 patients, we show that TGF-beta expression is also increased in patients' peripheral blood mononuclear cells (PBMC): (i) at the mRNA level analysed by Northern blot hybridization and/or reverse transcription-polymerase chain reaction (RT-PCR); (ii) and/or at the secreted peptide level as evaluated in conditioned media from patients' mononuclear cells by a growth inhibition assay on CC164 cells. By immunostaining with a polyclonal anti-TGF-beta 1 antibody, TGF-beta was localized in morphologically heterogenous cells; these cells were characterized as megakaryocytes by labelling with a gpIIbIIIa monoclonal antibody. Thus we provide evidence that both TGF-beta and megakaryocytes are linked in the pathogenesis of idiopathic myelofibrosis.
Insights
Transforming growth factor-beta (TGF-beta) is elevated in idiopathic myelofibrosis patients. This study links increased TGF-beta expression in peripheral blood mononuclear cells and megakaryocytes to the disease pathogenesis.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Idiopathic myelofibrosis (IMF) is a myeloproliferative neoplasm characterized by bone marrow fibrosis.
- The exact pathogenesis of bone marrow fibrosis in IMF remains incompletely understood.
- Previous research indicated elevated intraplatelet transforming growth factor-beta (TGF-beta) in IMF patients.
Purpose of the Study:
- To investigate the expression and localization of TGF-beta in peripheral blood mononuclear cells (PBMC) of IMF patients.
- To explore the potential role of TGF-beta and megakaryocytes in the pathogenesis of idiopathic myelofibrosis.
Main Methods:
- Analysis of TGF-beta mRNA levels in PBMCs using Northern blot hybridization and RT-PCR.
- Assessment of secreted TGF-beta peptide levels in conditioned media from PBMCs via a growth inhibition assay.
- Immunostaining of PBMCs with anti-TGF-beta 1 antibody and gpIIbIIIa monoclonal antibody to identify cell types.
Main Results:
- TGF-beta expression was significantly increased at both mRNA and secreted peptide levels in PBMCs from IMF patients compared to healthy controls.
- Immunostaining revealed TGF-beta localized within megakaryocytes in the peripheral blood.
- These findings establish a direct link between TGF-beta and megakaryocytes in IMF pathogenesis.
Conclusions:
- Increased TGF-beta expression in PBMCs, particularly within megakaryocytes, is a key feature of idiopathic myelofibrosis.
- TGF-beta and megakaryocytes play a significant role in the underlying mechanisms driving bone marrow fibrosis in IMF.
- This study provides critical insights into the molecular pathogenesis of idiopathic myelofibrosis, suggesting potential therapeutic targets.